GLP-1, Parkinson's Disease, and Neuroprotection
When in doubt, starting fresh with new reconstitution or a new vial is safer than continuing with potentially degraded peptide
In a 2023 study investigating GHS-based treatments for neurodegenerative diseases like amyotrophic lateral sclerosis (ALS), hexarelin was one of two GHSs chosen for experimentation
Strehlow K, Rotter S, Wassmann S, Adam O, Groh C, Laufs K, et al
The study also revealed that 43 percent of adults with diabetes and 26 percent of those with heart disease reported using a GLP-1 RA
Its prolonged use can lead to dependence, meaning the brain will rely on this medication to produce adequate amounts of epinephrine and dopamine, she says